Entera Bio (NASDAQ:ENTX - Get Free Report) was upgraded by equities research analysts at HC Wainwright to a "strong-buy" rating in a report issued on Monday,Zacks.com reports. HC Wainwright also issued estimates for Entera Bio's Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.67) EPS.
Entera Bio Trading Up 1.5%
NASDAQ ENTX traded up $0.03 on Monday, hitting $2.00. 76,554 shares of the company were exchanged, compared to its average volume of 292,475. The company has a market cap of $91.32 million, a PE ratio of -7.69 and a beta of 1.52. Entera Bio has a 12 month low of $1.50 and a 12 month high of $2.79. The stock has a fifty day moving average of $1.95 and a 200-day moving average of $1.99.
Entera Bio (NASDAQ:ENTX - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 77.75%. On average, analysts expect that Entera Bio will post -0.28 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Knoll Capital Management LLC lifted its position in shares of Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after purchasing an additional 2,000,000 shares in the last quarter. Parkman Healthcare Partners LLC increased its holdings in Entera Bio by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock worth $747,000 after buying an additional 25,900 shares during the last quarter. Northern Trust Corp purchased a new stake in Entera Bio during the fourth quarter worth about $450,000. Bessemer Group Inc. purchased a new stake in Entera Bio during the second quarter worth about $268,000. Finally, HighTower Advisors LLC increased its holdings in Entera Bio by 53.3% during the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock worth $31,000 after buying an additional 6,310 shares during the last quarter. 14.11% of the stock is owned by institutional investors.
About Entera Bio
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Further Reading
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access